Breaking Down SG&A Expenses: Zoetis Inc. vs TG Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, understanding the financial health of a company is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and TG Therapeutics, Inc. from 2014 to 2023. Over this period, Zoetis Inc. consistently outpaced TG Therapeutics, Inc. in SG&A spending, reflecting its larger scale and market presence. In 2023, Zoetis Inc.'s SG&A expenses were approximately 17 times higher than those of TG Therapeutics, Inc., highlighting its expansive operations.

Key Insights

• Zoetis Inc.: From 2014 to 2023, Zoetis Inc. saw a steady increase in SG&A expenses, peaking in 2023 with a 31% rise from 2014.
• TG Therapeutics, Inc.: Despite fluctuations, TG Therapeutics, Inc. experienced a significant surge in 2021, with expenses nearly doubling from the previous year.

This financial snapshot offers a window into the strategic priorities and growth trajectories of these two industry players.